BHVN Biohaven Pharmaceutical Holding Company Ltd.

69.39
-1.53  -2%
Previous Close 70.92
Open 70.22
52 Week Low 31.86
52 Week High 100.77
Market Cap $4,483,917,753
Shares 62,040,504
Float 57,252,440
Enterprise Value $4,494,908,940
Volume 439,782
Av. Daily Volume 638,882
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Nurtec (Rimegepant)
Migraine - preventative
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Verdiperstat (HEALEY ALS Platform Trial)
Amyotrophic lateral sclerosis (ALS)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Verdiperstat
Multiple system atrophy (MSA)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Troriluzole
Spinocerebellar Ataxia (SCA)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Troriluzole
Obsessive compulsive disorder (OCD)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Oral Zavegepant
Migraine
Phase 2/3
Phase 2/3
Phase 2/3 commencement of enrollment announced March 29, 2021.
Troriluzole
Alzheimer’s disease
Phase 2
Phase 2
Phase 2/3 top-line data did not meet co-primary endpoints - January 18, 2021.
Rimegepant
Refractory trigeminal neuralgia
Phase 2
Phase 2
Phase 2 trial continues to enrol as of August 2020.
Vazegepant
COVID-19 Coronavirus associated pulmonary complications
Phase 1
Phase 1
Phase 1 dosing commenced September 2020.
TRORILUZOLE
Generalized anxiety disorder (GAD)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - February 10, 2020.
Rimegepant Zydis ODT
Acute treatment of migraine
Approved
Approved
FDA Approval announced February 27, 2020.
Nurtec (riluzole) (BHV-0223)
Amyotrophic lateral sclerosis (ALS)
CRL
CRL
CRL issued July 19, 2019.

Latest News

  1. NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN, the ", Company", or ", Biohaven", ))), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021. 

    Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of March 31, 2021) were over 500,000, with over 30,000 unique prescribers. 

    The foregoing information reflects the Company's estimate with respect to net product revenue for NURTEC ODT based on currently available information which is preliminary and unaudited, is not a comprehensive statement of the Company's financial results and is subject to completion of the Company's financial closing procedures. The Company's final results that will be issued upon completion of its closing procedures may vary from these preliminary estimates. 

    Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "Despite the typical first quarter insurance dynamics associated with new year prior authorizations/deductibles and the winter surge of COVID-19 affecting prescription volumes, NURTEC ODT continues to grow quarter over quarter in both prescription volume and net revenue. Our commercial team continues to build strong momentum for the brand as we also receive positive feedback from patients and physicians regarding the important role that NURTEC ODT is playing in the acute treatment of migraine.  The impressive market growth of NURTEC ODT reflects the significant unmet need that exists for patients suffering from the debilitating effects of acute migraine, our strong commercial and managed markets team, and the differentiated product label compared to competitors. We're proud of our commercial and R&D team members who remain dedicated to delivering this important medication to patients and we look forward to improved market dynamics as COVID-19 subsides with the increasing rollout of multiple vaccines."

    BJ Jones, Chief Commercial Officer, added, "NURTEC ODT continues to demonstrate strong prescription growth and increases in quarterly net revenue. We are beginning to see in-market dynamics improve as the vaccines roll out and look forward to continued market growth for this important new acute treatment of migraine."

    Rimegepant is marketed as NURTEC ODT, and is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in an orally disintegrating tablet (ODT) designed for rapid onset of action and sustained efficacy for 48 hours. Rimegepant was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in February 2020, with commercial launch commencing the second week of March 2020. 

    About Biohaven

    Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

    Forward-Looking Statements

    This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's business and product candidate plans and objectives are forward-looking statements. Forward-looking statements include those related to: the preliminary nature of net product revenues for NURTEC ODT,  commercialization and sales of NURTEC ODT and the potential approval and commercialization of other product candidates, the effect of the ongoing COVID-19 pandemic on Biohaven, the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, including the need for any REMS or Advisory Committee meetings, the potential for Biohaven's product candidates to be first in class or best in class therapies and the effectiveness and safety of Biohaven's product candidates. The use of certain words, including "believe", "continue", "may", "on track", "expects" and "will" and similar expressions, are intended to identify forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Biohaven's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    About NURTEC ODT

    NURTEC® ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. The safety of treating up to 15 migraines in a 30-day period has been established. For more information about NURTEC ODT, visit www.nurtec.com.

    About Migraine

    Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia). There is a significant unmet need for new acute treatments as more than 90 percent of migraine sufferers are unable to work or function normally during an attack.

    About CGRP Receptor Antagonism

    Small molecule CGRP receptor antagonists represent a novel class of drugs for the treatment of migraine. This unique mode of action potentially offers an alternative to current agents, particularly for patients who have contraindications to the use of triptans, or who have a poor response to triptans or are intolerant to them.

    Indication

    NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults.

    Limitations of Use

    NURTEC ODT is not indicated for the preventive treatment of migraine.

    Important Safety Information

    Contraindications: Hypersensitivity to NURTEC ODT or any of its components.

    Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy.  Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

    Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% in patients who received placebo).  Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with NURTEC ODT.

    Drug Interactions: Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP.  Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

    Use in Specific Populations:

    1. Pregnant/breast feeding: It is not known if NURTEC ODT can harm an unborn baby or if it passes into breast milk.
    2. Hepatic impairment: Avoid use of NURTEC ODT in persons with severe hepatic impairment.
    3. Renal impairment: Avoid use in patients with end-stage renal disease. 

    Please click here for full Prescribing information.

    You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4Nurtec.

    Please click here for full Prescribing information and Patient Information.

    Biohaven Contact

    Dr. Vlad Coric

    Chief Executive Officer

    For Media

    Mike Beyer

    Sam Brown Inc. 



    312-961-2502

    NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-preliminary-1q2021-net-product-revenue-for-nurtec-odt-301264000.html

    SOURCE Biohaven Pharmaceutical Holding Company Ltd.

    View Full Article Hide Full Article
  2. MOORESVILLE, N.C., April 6, 2021 /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlotte Motor Speedway. For the first time in NASCAR history, one NASCAR Cup Series team will represent the four branches of the military. Driving the Rick Ware Racing cars are #51 (Nurtec ODT) Air Force, Garret Smithley; #52 Army, Josh Bilicki; #53 Marines, JJ Yeley and #15 Navy, James Davison.

    Nine Line Apparel will offer a commemorative t-shirt honoring the fallen service members. Through the purchase of each t-shirt, the buyer can submit the name of a fallen service member to run on the hood of the respective branch for which they served. A portion of the proceeds will be donated to 22 Until None, a non-profit dedicated to ending veteran suicide, one step at a time. More than 8,000 veterans a year commit suicide, which is 200% more likely to happen after active military service. 22 Until None helps to provide financial assistance, health and wellness, camaraderie and advocacy for the battle that continues once returning home.

    "We are beyond grateful for the opportunity to honor our nation's heroes in the Coca-Cola 600 at Charlotte Motor Speedway," commented team owner Rick Ware. "Nurtec ODT and Nine Line Apparel are both huge advocates for our active-duty service members and veterans. Working together with both organizations to create this opportunity, is very special for Rick Ware Racing as well as all of the family members who have lost someone who has served this great country."

    Prior to the 2021 NASCAR Cup Series season, Rick Ware Racing and Biohaven's Nurtec ODT joined together to create a Military Salutes program to support and thank active-duty service members. The Rick Ware Racing team and the #51 Nurtec ODT show car have currently visited 10 bases and plan to visit approximately 40+ more throughout the year. At each visit, service members can participate in mock pit stops, photos with the car and a driver meet-and-greet.

    Vlad Coric, M.D., CEO of Biohaven said, "We are very proud to be a part of the Rick Ware Racing team and work with Nine Line Apparel on such a meaningful opportunity to honor fallen service members. Through the Military Salutes Program, we have been able to spend time with active-duty service members, veterans and their families and hear their migraine stories. We know that there are unique challenges faced by this population including a disproportionate impact of migraine and are grateful to have the opportunity to raise the level of discussion about this debilitating disease."

    "As a veteran owned, giveback organization, our brand was built on the foundation of honoring those heroes we've lost on the battlefield, and supporting those still struggling back home," said Rich Caponi, Chief Marketing Officer of Nine Line. "We know that Rick Ware Racing and the Nurtec ODT team share this same passion, which is why we're proud to partner with them on this initiative. Memorial Day Weekend in Charlotte will be a time to honor the heroes who have given their lives in service to this great country, while also raising awareness and support for veterans fighting internal battles on the home front."

    For additional information on Nurtec ODT, visit www.nurtec.com. Follow Rick Ware Racing, by visiting www.wareracing.com, and be sure to follow along on social media (Facebook, Twitter and/or Instagram). 

    About Rick Ware Racing

    With a rich and extensive history, Rick Ware Racing has been part of the racing fabric in the USA for over 30 years. The team has recently competed in both Prototypes and the NASCAR Cup Series. The team most recently claimed the 2020 Asian Le Mans Series Am Championship. For more information on Rick Ware Racing, visit www.wareracing.com

    About Nine Line

    Founded in 2012 by Army Captain and former Special Operations Air Mission Commander Tyler Merritt, Nine Line Apparel is a patriotic lifestyle brand based out of Savannah, Georgia. Nine Line is known for their patriotic designs, and as a give-back organization that supports our nation's veterans and first responders through the Nine Line Foundation and other non-profit initiatives. To learn more, visit ninelineapparel.com.   

    About Biohaven

    Biohaven (NYSE:BHVN) is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

    About NURTEC ODT

    NURTEC® ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. For more information about NURTEC ODT, visit www.nurtec.com

    Indication

    NURTEC® ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

    Limitations of Use

    NURTEC ODT is not indicated for the preventive treatment of migraine.

    Important Safety Information

    Contraindications: Hypersensitivity to NURTEC ODT or any of its components.

    Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

    Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received NURTEC ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with NURTEC ODT.

    Drug Interactions: Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of NURTEC ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

    Use in Specific Populations:

    Pregnant/breast feeding: It is not known if NURTEC ODT can harm an unborn baby or if it passes into breast milk.   

    Hepatic impairment: Avoid use of NURTEC ODT in persons with severe hepatic impairment.   

    Renal impairment: Avoid use in patients with end-stage renal disease.

    Please click here for full Prescribing Information.

    You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects to Biohaven at 1-833-4Nurtec. 

    Please click here for full Prescribing Information and Patient Information.

    NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC

    Biohaven Contact:

    Vlad Coric, M.D.

    Chief Executive Officer

    Media Contact:

    Mike Beyer

    Sam Brown Inc.



    312-961-2502

    Rick Ware Racing Contact:

    Kate Fegley



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rick-ware-racing-biohavens-nurtec-odt-and-nine-line-apparel-honor-fallen-service-members-301262721.html

    SOURCE Biohaven Pharmaceutical Holding Company Ltd.

    View Full Article Hide Full Article
  3. NEW HAVEN, Conn., March 29, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that it has enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine.  

    In August 2020, Biohaven entered into a funding agreement with Royalty Pharma to secure up to $250 million to advance the development of zavegepant in migraine and other CGRP-mediated diseases.  Biohaven previously received $150 million in funding and will now receive $100 million with the enrollment of this first patient in the oral zavegepant Phase 3 clinical trial.

    Elyse Stock, M.D., Chief Medical Officer of Biohaven commented, "We are excited to advance the oral formulation of zavegepant into this late-stage, clinical trial and broaden our CGRP franchise. We plan on following the science of CGRP receptor antagonism into pain related disorders and non-migraine indications. By expanding beyond our migraine franchise, we are hoping to meet the needs of people impacted by the debilitating aspects of multiple CGRP-mediated diseases."

    The randomized, double-blind, placebo-controlled trial will enroll approximately 2,900 people with migraine and will evaluate the efficacy and safety of 100 mg and 200 mg doses of oral zavegepant. For more information about the trial, visit clinicaltrials.gov.

    "We are pleased to see Biohaven progress oral zavegepent into Phase 3 for the prevention of migraine, as people suffering from frequent migraines continue to need additional treatment options," said Jim Reddoch, PhD, Royalty Pharma's Co-Head of Research & Investments and Chief Scientific Officer. "Our successful, multi-year partnership with Biohaven to support both the regulatory approval and commercialization of Nurtec as well as pipeline development is an excellent example of how Royalty Pharma can be a collaborative partner to innovative biopharma companies." 

    The zavegepant program encompasses intranasal and oral formulations for migraine and non-migraine indications. Intranasal zavegepant previously demonstrated superior efficacy to placebo in a Phase 2/3 study for the acute treatment of migraine and the investigational agent is also being studied in an ongoing double blind, randomized, placebo-controlled trial in COVID-19 infected hospitalized patients requiring supplemental oxygen.

    About Biohaven

    Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine and non-migraine CGRP-mediated diseases; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis. More information about Biohaven is available at www.biohavenpharma.com.

    Forward-Looking Statements

    This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe", "continue", "may", "will" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven's management about zavegepant as an acute and preventive treatment for patients with migraine and non-migraine CGRP-mediated diseases. Factors that could affect these forward-looking statements include those related to: Biohaven's ability to effectively commercialize zavegepant, delays or problems in the supply or manufacture of zavegepant, complying with applicable U.S. regulatory requirements, the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, the timing of planned interactions and filings with the FDA, the timing and outcome of expected regulatory filings, the potential commercialization of Biohaven's product candidates, the potential for Biohaven's product candidates to be first in class or best in class therapies and the effectiveness and safety of Biohaven's product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Biohaven's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 1, 2021. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    NOJECTION and NURTEC are trademarks of Biohaven Pharmaceutical Ireland DAC.

    Contact:

    Dr. Vlad Coric

    Chief Executive Officer

    Phone: (203) 404-0410

    Email: 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-enrolls-first-patient-in-phase-23-trial-of-oral-zavegepant-prompting-100-million-milestone-funding-payment-from-royalty-pharma-301257256.html

    SOURCE Biohaven Pharmaceutical Holding Company Ltd.

    View Full Article Hide Full Article
  4. NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.  In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.  The gross proceeds from the offering are expected to be approximately $200 million

    NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.  In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions.  The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Biohaven.  The offering is expected to close on March 17, 2021, subject to satisfaction of customary closing conditions.

    Goldman Sachs & Co. LLC is acting as the book-running manager of the offering.

    The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1–866-471-2526, facsimile: 212-902-9316 or by emailing .

    The shares will be issued pursuant to an effective shelf registration statement on Form S-3.  Copies of the registration statement can be accessed through the SEC's website at www.sec.gov.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

    Contact

    Dr. Vlad Coric

    Chief Executive Officer

    Biohaven Pharmaceutical Holding Company Ltd.

    Phone: (203) 404-0410

    Email:

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-pricing-of-200-million-public-offering-of-common-shares-301247797.html

    SOURCE Biohaven Pharmaceutical Holding Company Ltd.

    View Full Article Hide Full Article
  5. NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $200 million of its common shares.  All of the common shares to be sold in the offering will be offered by Biohaven.  In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $30 million of common shares at the public offering price, less underwriting discounts and commissions.  The offering is subject…

    NEW HAVEN, Conn., March 15, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $200 million of its common shares.  All of the common shares to be sold in the offering will be offered by Biohaven.  In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $30 million of common shares at the public offering price, less underwriting discounts and commissions.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

    Goldman Sachs & Co. LLC is acting as the book-running manager of the offering.

    The offering is being made only by means of a prospectus supplement and the accompanying prospectus, copies of which, when available, may be obtained from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1–866-471-2526, facsimile: 212-902-9316 or by emailing .

    The shares will be issued pursuant to an effective shelf registration statement on Form S-3.  Before investing in the offering, interested parties should read the prospectus and related prospectus supplement for this offering, the documents incorporated by reference therein and the other documents Biohaven has filed with the Securities and Exchange Commission.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

    Contact

    Dr. Vlad Coric

    Chief Executive Officer

    Biohaven Pharmaceutical Holding Company Ltd.

    Phone: (203) 404-0410

    Email:

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-301247671.html

    SOURCE Biohaven Pharmaceutical Holding Company Ltd.

    View Full Article Hide Full Article
View All Biohaven Pharmaceutical Holding Company Ltd. News